Tandem Diabetes Care Inc (NASDAQ:TNDM) Director Douglas A. Roeder sold 13,347 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $70.08, for a total transaction of $935,357.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
TNDM opened at $62.84 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.13 and a current ratio of 2.43. The company has a fifty day moving average price of $65.91. Tandem Diabetes Care Inc has a 1 year low of $24.03 and a 1 year high of $74.81. The firm has a market cap of $3.66 billion, a PE ratio of -24.64 and a beta of 0.41.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative net margin of 50.73% and a negative return on equity of 40.76%. The firm had revenue of $66.00 million during the quarter, compared to analyst estimates of $47.55 million. During the same quarter in the prior year, the firm earned ($1.82) earnings per share. The business’s revenue for the quarter was up 141.9% on a year-over-year basis. Analysts forecast that Tandem Diabetes Care Inc will post -0.81 earnings per share for the current fiscal year.
Several analysts have recently commented on TNDM shares. Leerink Swann started coverage on shares of Turning Point Therapeutics in a report on Monday, May 13th. They issued an “outperform” rating and a $42.00 price objective on the stock. UBS Group upped their price objective on shares of Spotify Technology from $180.00 to $182.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Oppenheimer upped their price objective on shares of Paycom Software from $175.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Bank of America set a $120.00 price objective on shares of Walmart and gave the company a “buy” rating in a report on Friday, May 17th. Finally, BidaskClub downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $68.13.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Further Reading: Stochastic Momentum Index (SMI)
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.